Overview Dividends

(KIDS) Orthopediatrics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68752L1008

Implants, Braces, Trauma, Deformity, Scoliosis

KIDS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 92.69%
EPS Trend (3Y Correlation): 35.2%

KIDS Revenue

Revenue Growth (3Y CAGR): 22.51%
Revenue Trend (3Y Correlation): 93.8%

Description: KIDS Orthopediatrics October 24, 2025

OrthoPediatrics Corp. (NASDAQ: KIDS) designs, develops, and markets a portfolio of anatomically-specific implants, instruments, and braces for children with orthopedic conditions, serving both U.S. and international markets. Its product suite spans pediatric trauma and deformity correction, scoliosis spinal devices, sports-medicine solutions, and growth-modulation systems, including proprietary lines such as PediLoc, the Fassier-Duval telescopic intramedullary system, and the Boston Brace 3D. Founded in 2006 and headquartered in Warsaw, Indiana, the company targets pediatric orthopedic surgeons and caregivers.

Key metrics and sector dynamics that currently shape KIDS’ outlook include: (1) FY 2024 revenue of roughly $115 million, reflecting a 12% year-over-year increase driven by higher adoption of minimally invasive growth-modulation products; (2) a pediatric orthopedic market projected to grow at a 7-9% CAGR through 2030, buoyed by rising incidence of pediatric fractures and expanding insurance coverage for early-intervention surgeries; and (3) regulatory headwinds-each new implant requires FDA 510(k) clearance, which can add 6-12 months to product rollout timelines, creating a material timing risk for pipeline launches.

For a deeper quantitative assessment of KIDS’ valuation assumptions and scenario analysis, the ValueRay platform offers a transparent, data-driven model worth reviewing.

KIDS Stock Overview

Market Cap in USD	432m
Sub-Industry	Health Care Supplies
IPO / Inception	2017-10-12

KIDS Stock Ratings

Growth Rating	-83.9%
Fundamental	30.3%
Dividend Rating	-
Return 12m vs S&P 500	-46.0%
Analyst Rating	4.29 of 5

KIDS Dividends

Currently no dividends paid

KIDS Growth Ratios

Growth Correlation 3m	-72.3%
Growth Correlation 12m	-84.2%
Growth Correlation 5y	-89.5%
CAGR 5y	-23.82%
CAGR/Max DD 3y (Calmar Ratio)	-0.35
CAGR/Mean DD 3y (Pain Ratio)	-0.61
Sharpe Ratio 12m	-0.78
Alpha	-54.36
Beta	1.021
Volatility	44.92%
Current Volume	146k
Average Volume 20d	166k
Stop Loss	16 (-5.4%)
Signal	0.22

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-41.8m TTM) > 0 and > 6% of Revenue (6% = 13.2m TTM)

FCFTA -0.07 (>2.0%) and ΔFCFTA 4.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 99.23% (prev 88.09%; Δ 11.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.06 (>3.0%) and CFO -28.9m > Net Income -41.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 6.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (23.3m) change vs 12m ago 0.87% (target <= -2.0% for YES)

Gross Margin 71.54% (prev 65.89%; Δ 5.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 47.25% (prev 40.64%; Δ 6.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.14 (EBITDA TTM -16.7m / Interest Expense TTM 3.96m) >= 6 (WARN >= 3)

Altman Z'' -1.14

(A) 0.43 = (Total Current Assets 257.7m - Total Current Liabilities 38.7m) / Total Assets 503.6m

(B) -0.50 = Retained Earnings (Balance) -253.3m / Total Assets 503.6m

(D) -1.74 = Book Value of Equity -258.3m / Total Liabilities 148.1m

Total Rating: -1.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.30

1. Piotroski 1.50pt = -3.50

2. FCF Yield -8.20% = -4.10

3. FCF Margin -17.07% = -6.40

4. Debt/Equity 0.27 = 2.46

5. Debt/Ebitda -3.14 = -2.50

6. ROIC - WACC (= -16.56)% = -12.50

7. RoE -11.70% = -1.95

8. Rev. Trend 93.80% = 7.03

9. EPS Trend 35.16% = 1.76

What is the price of KIDS shares?

As of October 29, 2025, the stock is trading at USD 16.91 with a total of 146,042 shares traded.
Over the past week, the price has changed by -5.56%, over one month by -7.65%, over three months by -24.48% and over the past year by -35.29%.

Is Orthopediatrics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Orthopediatrics (NASDAQ:KIDS) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.30 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KIDS is around 11.72 USD . This means that KIDS is currently overvalued and has a potential downside of -30.69%.

Is KIDS a buy, sell or hold?

Orthopediatrics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy KIDS.

Strong Buy: 3
Buy: 3
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KIDS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	26.3	55.5%
Analysts Target Price	26.3	55.5%
ValueRay Target Price	13	-22.9%

KIDS Fundamental Data Overview October 18, 2025

Market Cap USD = 432.3m (432.3m USD * 1.0 USD.USD)
P/S = 1.9583
P/B = 1.2646
Beta = 1.021
Revenue TTM = 220.7m USD
EBIT TTM = -36.2m USD
EBITDA TTM = -16.7m USD
Long Term Debt = 97.0m USD (from longTermDebt, last quarter)
Short Term Debt = 164.0k USD (from shortTermDebt, last quarter)
Debt = 97.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 52.6m USD (from netDebt column, last quarter)
Enterprise Value = 459.3m USD (432.3m + Debt 97.2m - CCE 70.1m)
Interest Coverage Ratio = -9.14 (Ebit TTM -36.2m / Interest Expense TTM 3.96m)
FCF Yield = -8.20% (FCF TTM -37.7m / Enterprise Value 459.3m)
FCF Margin = -17.07% (FCF TTM -37.7m / Revenue TTM 220.7m)
Net Margin = -18.92% (Net Income TTM -41.8m / Revenue TTM 220.7m)
Gross Margin = 71.54% ((Revenue TTM 220.7m - Cost of Revenue TTM 62.8m) / Revenue TTM)
Gross Margin QoQ = 72.07% (prev 73.00%)
Tobins Q-Ratio = 0.91 (Enterprise Value 459.3m / Total Assets 503.6m)
Interest Expense / Debt = 1.15% (Interest Expense 1.12m / Debt 97.2m)
Taxrate = -0.69% (negative due to tax credits) (49.0k / -7.06m)
NOPAT = -36.5m (EBIT -36.2m * (1 - -0.69%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 6.66 (Total Current Assets 257.7m / Total Current Liabilities 38.7m)
Debt / Equity = 0.27 (Debt 97.2m / totalStockholderEquity, last quarter 355.5m)
Debt / EBITDA = -3.14 (negative EBITDA) (Net Debt 52.6m / EBITDA -16.7m)
Debt / FCF = -1.40 (negative FCF - burning cash) (Net Debt 52.6m / FCF TTM -37.7m)
Total Stockholder Equity = 357.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.29% (Net Income -41.8m / Total Assets 503.6m)
RoE = -11.70% (Net Income TTM -41.8m / Total Stockholder Equity 357.0m)
RoCE = -7.98% (EBIT -36.2m / Capital Employed (Equity 357.0m + L.T.Debt 97.0m))
RoIC = -8.37% (negative operating profit) (NOPAT -36.5m / Invested Capital 436.1m)
WACC = 8.20% (E(432.3m)/V(529.4m) * Re(9.78%) + D(97.2m)/V(529.4m) * Rd(1.15%) * (1-Tc(-0.01)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.27%
Fair Price DCF = unknown (Cash Flow -37.7m)
EPS Correlation: 35.16 | EPS CAGR: 92.69% | SUE: 3.04 | # QB: 2
Revenue Correlation: 93.80 | Revenue CAGR: 22.51% | SUE: -0.30 | # QB: 0

Additional Sources for KIDS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle